Context Therapeutics Inc. CNTX
0.19 USD -0.01 (-6.64%)
At closeNov 10, 2026, 7:29 PM EST
0.20 +0.01 +5.83%
After hours · Nov 10, 7:29 PM ET
0.1862 Day range 0.2009
0.187 52-week range 3.36
- YTD
- -87.28%
- 1 year
- -84.42%
News
benzinga.com Context Therapeutics Q3 EPS $(0.08) Beats $(0.11) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 20 percent increase over losses of…
globenewswire.com Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
zacks.com New Strong Sell Stocks for October 15th CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
zacks.com New Strong Sell Stocks for October 13th ATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.
globenewswire.com Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser…
benzinga.com Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.
benzinga.com Context Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 66.67 percent decrease over losses…
globenewswire.com Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund…
globenewswire.com Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific…
benzinga.com Context Therapeutics Added To Russell 2000, Russell 3000 Indexes, Effective June 26 Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today
globenewswire.com Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”)…- benzinga.com Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4 Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $8 to $4.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLDN6 x CD3 T-cell engaging bispecific antibody, showing early signs of efficacy and a favorable…
benzinga.com Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with favorable safety data.
benzinga.com Context Therapeutics Announces Interim Phase 1 Clinical Data For CLDN6 X CD3 T Cell Engaging Bispecific Antibody, CTIM-76, In Advanced, Late-Line Platinum-Resistant Ovarian Cancer 29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapyCytokine Release Syndrome ("CRS")…
globenewswire.com Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
globenewswire.com Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
globenewswire.com Context Therapeutics to Present at the Jefferies Global Healthcare Conference PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific…
globenewswire.com Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license- benzinga.com Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 80 percent decrease over losses of…
globenewswire.com Context Therapeutics Reports First Quarter 2026 Operating and Financial Results Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202…
benzinga.com Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today…
globenewswire.com Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02,…
defenseworld.net Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are currently covering the stock, MarketBeat…
defenseworld.net Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX) Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price target.
benzinga.com Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7 Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.- benzinga.com Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 34.62 percent.
globenewswire.com Context Therapeutics Reports Full Year 2025 Operating and Financial Results Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash…
globenewswire.com Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”)…
defenseworld.net Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference Context Therapeutics (NASDAQ: CNTX) CEO Martin Lehr outlined the company's strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology…
defenseworld.net Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages Shares of Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket 
benzinga.com This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7 Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
- benzinga.com D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5 HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
- benzinga.com Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses…
- benzinga.com D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
benzinga.com Context Therapeutics To Present Cancer Immunotherapy Data At SITC 2025 Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today…
benzinga.com This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday